Objective: Clinical trials demonstrate improved glycemic control with HCL insulin delivery systems, yet limited real-world data exists substantiating these findings. Data from the inaugural cohort of patients initiating a HCL system (Medtronic 670G) at a university medical center was used to examine real-world utilization, adherence, and glycemic control over the first 6-12 weeks of pump use.

Research Design and Methods: Data from 35 patients with type 1 diabetes (22-72 years of age) were obtained from insulin pump downloads at 4 time points: previous insulin pump, HCL start in manual-mode, 2-weeks after auto-mode transition, and between 6-12 weeks after HCL start. In person training by certified diabetes educators was performed for manual-mode, sensor initiation, and auto-mode with phone and electronic messaging following initiation of auto-mode.

Results: A total of 46 patients received HCL between June 1 and December 31 of 2017. Of these, 7 patients did not have sensors allowing them to initiate HCL, 3 did not have a 6-12 week download, and 1 never transitioned into auto-mode. Mean self-monitoring blood glucose (SMBG) per day increased from 5.15 baseline to 6.49 at 6-12 weeks (p<0.05) with 3.26 sensor calibrations per day. Time in auto-mode was 79.3% at 2 weeks, and 71.7% by 6-12 weeks with 82% of patients spending >50% of time in auto-mode. Over the 14-day final download there were 8.2 auto-mode exits. Time in target was 65.5% in manual-mode, 73.4% at 2-weeks (p=0.09), and 71.7% by 6-12 weeks (p=0.06). HbA1C decreased 0.51% (p=0.02), total daily dose increased (p=0.027), while basal-to-bolus ratio did not change over the study period. Baseline mean SMBG and HbA1C, but not basal:bolus ratio, bolus calculator use, or bolus frequency, were significant predictors of time in auto-mode and time-in-target at 6-12 weeks.

Conclusions: These data illustrate real-world implementation of HCL technology within a major medical center. Patients initiating HCL achieved acceptable time-in-auto mode and time-in-target range.

Disclosure

E.R. Faulds: Other Relationship; Self; A1Contro, LLC. K.M. Dungan: Research Support; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi-Aventis. Research Support; Self; Sanofi-Aventis, GlaxoSmithKline plc.. Consultant; Self; GlaxoSmithKline plc.. Research Support; Self; AstraZeneca. Other Relationship; Self; DKBmed, Horizon, Projects in knowledge, Rockpointe.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.